

North America ACE Inhibitors Market By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drugs (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others), By End user (Hospitals, Online Drug Stores, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F

Market Report | 2024-10-04 | 136 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4400.00
- Multi-User License \$5400.00
- Custom Research License \$8400.00

Report description:

North America ACE Inhibitors Market was valued at USD 2.18 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.25% through 2029.

The ACE Inhibitors Market holds a pivotal position in the pharmaceutical industry, addressing the treatment needs of cardiovascular diseases, particularly hypertension and heart failure. These medications play a vital role in relaxing blood vessels, reducing blood pressure, and alleviating the strain on the heart. With cardiovascular diseases on the rise in North America, the demand for effective treatments like ACE inhibitors continues to grow. The aging population, coupled with increasing awareness of hypertension risks, further drives market expansion. The improvements in healthcare infrastructure contribute to better diagnosis and treatment access, fueling market growth. ACE inhibitors are extensively used in managing hypertension, heart failure, and post-heart attack care. They also exhibit efficacy in slowing kidney disease progression in diabetic patients and preventing cardiovascular events in high-risk individuals. The market boasts a competitive landscape with key players like Pfizer, Novartis, and AstraZeneca actively involved in drug production and distribution. Intense competition drives innovation, pricing strategies,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and strategic collaborations. The ACE Inhibitors Market is poised for sustained growth, fueled by the rising burden of cardiovascular diseases and ongoing research and development efforts to enhance existing drugs and develop novel therapies. With a focus on improving cardiovascular health and preventing complications, ACE inhibitors remain indispensable in cardiovascular drug therapy, ensuring a promising future for the market.

Key Market Drivers

Rising prevalence of cardiovascular diseases

The increasing incidence of cardiovascular diseases (CVDs) stands as a primary catalyst propelling the ACE Inhibitors Market forward. These conditions, which encompass hypertension, heart failure, and chronic kidney disease, remain significant contributors to global health burdens. Factors such as sedentary lifestyles, poor dietary habits, and aging populations contribute to the escalating prevalence of CVDs, underscoring the urgent need for effective therapeutic interventions. Cardiovascular disease (CVD) continues to be the leading cause of death in the United States, accounting for 928,741 fatalities in 2020. Within this category, coronary heart disease (CHD) was the predominant cause, responsible for 41.2% of CVD-related deaths. Following CHD, stroke accounted for 17.3%, other cardiovascular diseases for 16.8%, high blood pressure for 12.9%, heart failure for 9.2%, and diseases of the arteries for 2.6%. These statistics underscore the significant impact of cardiovascular conditions on public health in the United States.

ACE inhibitors have emerged as cornerstone medications renowned for their efficacy in managing a spectrum of cardiovascular ailments. By antagonizing the angiotensin-converting enzyme (ACE), these drugs facilitate vasodilation and reduce cardiac workload, thereby offering substantial benefits in cardiovascular health management. The widespread acknowledgment of ACE inhibitors as first-line treatments for various cardiovascular conditions fuels their widespread adoption among healthcare practitioners and patients alike. The ongoing research and development endeavors within the pharmaceutical sector continually introduce novel ACE inhibitors boasting enhanced efficacy profiles and reduced side effects. In response to evolving patient needs and therapeutic demands, the ACE Inhibitors Market expands its product portfolio, offering a diverse array of treatment options tailored to different cardiovascular conditions. The escalating prevalence of cardiovascular diseases creates a conducive environment for the sustained growth of the ACE Inhibitors Market. Positioned as indispensable components in cardiovascular health management, ACE inhibitors continue to play a pivotal role in addressing the evolving needs of patients and healthcare systems worldwide.

Increasing awareness about hypertension

The ACE Inhibitors Market experiences significant momentum due to heightened awareness surrounding hypertension. This growing awareness prompts individuals to take proactive steps towards managing and treating hypertension, recognizing its potential risks and implications. In United States OF America, Nearly half of all adults, or 119.9 million individuals, have hypertension. Among these, only about 1 in 4, totaling 27.0 million, have their condition under control. Clinicians universally recommend lifestyle modifications for all adults with hypertension, which serves as the sole treatment for 25.0 million individuals, or 1 in 5.

Additionally, approximately 4 in 5 adults with hypertension, equating to 94.9 million people, are advised to take prescription medications. Many adults currently on antihypertensive medication may require dosage increases or additional medications to achieve proper blood pressure control; this group includes 33.2 million people, with over half of them, 18.8 million, having blood pressure readings of 140/90 mm Hg or higher. Furthermore, 34.8 million adults for whom hypertension medication is recommended remain untreated, and within this untreated group, 23.4 million have blood pressure levels of 140/90 mm Hg or higher. ACE inhibitors emerge as pivotal medications in this landscape, renowned for their effectiveness in blood pressure control and prevention of cardiovascular complications. Consequently, healthcare providers increasingly prescribe ACE inhibitors as primary treatment options, while patients become more knowledgeable about these medications. Various initiatives, including public health campaigns and educational programs led by healthcare professionals, contribute to disseminating information about hypertension and its associated health risks.

Through these efforts, individuals gain a better understanding of the importance of managing blood pressure to mitigate the risk of cardiovascular events like heart attacks and strokes. As a result, there is a growing demand for effective antihypertensive medications, with ACE inhibitors being prominently favored for their efficacy and safety profiles. This proactive stance towards hypertension management, driven by heightened awareness campaigns and recommendations from healthcare professionals,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

fuels the expansion of the ACE Inhibitors Market. This trend is anticipated to endure as societies and healthcare systems increasingly prioritize preventive measures, positioning ACE inhibitors as indispensable components in collective endeavors to combat and regulate hypertension effectively.

Key Market Challenges

Competition from other antihypertensive drugs

The ACE Inhibitors Market encounters a formidable challenge in the form of competition from other antihypertensive drugs. With advancements in the pharmaceutical industry, alternative classes of antihypertensive medications such as angiotensin II receptor blockers (ARBs), calcium channel blockers, and diuretics have emerged, offering a diverse array of treatment options. These alternatives may possess distinct mechanisms of action and varied side effect profiles, prompting healthcare providers to consider them as viable alternatives to ACE inhibitors for certain patients. Navigating this competitive landscape requires the ACE Inhibitors Market to address the preferences and specific needs of patients effectively. Healthcare providers must carefully evaluate the benefits and drawbacks of different antihypertensive drug classes to tailor treatment regimens that optimize patient outcomes. Pharmaceutical companies within the ACE Inhibitors Market must continue to innovate and differentiate their products to remain competitive. This may involve developing novel formulations, enhancing drug delivery mechanisms, or exploring combination therapies to offer unique value propositions to patients and healthcare providers alike. Despite the presence of alternative antihypertensive medications, ACE inhibitors retain a significant market share due to their established efficacy and safety profiles. However, maintaining this position requires ongoing efforts to adapt to evolving market dynamics and meet the evolving needs of patients and healthcare providers. By leveraging innovation and strategic marketing initiatives, the ACE Inhibitors Market can effectively navigate competition from other antihypertensive drugs and sustain its growth trajectory in the evolving pharmaceutical landscape.

Potential side effects and adverse reactions

Addressing potential side effects and adverse reactions represents a significant hurdle for the ACE Inhibitors Market, despite their proven efficacy in managing hypertension. While these medications effectively lower blood pressure by inhibiting the angiotensin-converting enzyme, they are associated with several adverse effects that can impact patient adherence and treatment outcomes. One common side effect of ACE inhibitors is a dry, persistent cough, which occurs due to increased bradykinin levels resulting from ACE enzyme inhibition. This adverse reaction can be bothersome for patients and may lead to discontinuation of therapy, affecting blood pressure control and overall cardiovascular health. ACE inhibitors can cause hypotension, especially in patients with volume depletion or renal impairment, leading to symptoms such as dizziness, lightheadedness, and syncope. Renal dysfunction, characterized by elevated serum creatinine and potassium levels, is another potential complication of ACE inhibitor therapy, particularly in patients with underlying kidney disease. To mitigate these challenges, ongoing research and development efforts focus on developing newer ACE inhibitor formulations with improved safety profiles. For instance, prodrugs like enalaprilat and Fosinopril undergo hepatic conversion to their active forms, potentially reducing the risk of adverse reactions. The healthcare providers play a crucial role in patient management by carefully monitoring individuals for side effects and adjusting treatment regimens as needed. Patient education about potential adverse reactions and the importance of medication adherence is also essential for optimizing treatment outcomes and minimizing the impact of side effects on patient care. By addressing these concerns comprehensively, the ACE Inhibitors Market can enhance patient satisfaction, improve treatment adherence, and ultimately contribute to better cardiovascular outcomes for individuals with hypertension.

Key Market Trends

Increased focus on combination therapies

One prominent trend shaping the ACE Inhibitors Market is the increasing adoption of combination therapies, which involves combining ACE inhibitors with other classes of antihypertensive medications to optimize treatment outcomes. This strategy has gained traction as healthcare providers seek more effective approaches to manage hypertension and related cardiovascular conditions. Combination therapies offer several advantages over monotherapy by targeting multiple pathways involved in blood pressure regulation. For example, combining ACE inhibitors with diuretics helps address volume overload and fluid retention, while combining them with calcium channel blockers or angiotensin receptor blockers (ARBs) targets different aspects of the renin-angiotensin-aldosterone system (RAAS). By targeting multiple mechanisms simultaneously, combination therapies can

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

achieve greater reductions in blood pressure compared to individual agents alone. The personalized medicine approach emphasizes tailoring treatments to individual patient characteristics and needs. Combination therapies allow healthcare providers to customize treatment regimens based on factors such as patient age, comorbidities, and response to initial therapy. This personalized approach improves treatment efficacy and patient adherence, ultimately leading to better clinical outcomes. Another benefit of combination therapies is the potential to mitigate side effects associated with higher doses of a single medication. By using lower doses of multiple agents, healthcare providers can achieve blood pressure control while minimizing adverse reactions. For instance, combining ACE inhibitors with diuretics may reduce the risk of hyperkalemia commonly associated with ACE inhibitor monotherapy. Pharmaceutical companies and healthcare providers are actively exploring and researching various combination therapies to optimize hypertension management. Clinical trials and studies are evaluating the safety, efficacy, and tolerability of different combinations, providing valuable insights into their role in cardiovascular disease management. As the evidence supporting combination therapies continues to grow, they are expected to play an increasingly prominent role in the treatment paradigm for hypertension and related cardiovascular diseases, driving growth and innovation in the ACE Inhibitors Market.

Personalized medicine approaches

The ACE Inhibitors Market is witnessing a significant shift towards personalized medicine approaches, where treatments are tailored to individual patient characteristics such as genetics, comorbidities, and lifestyle factors. This trend emphasizes the importance of genetic testing and biomarker analysis to identify the most appropriate antihypertensive medication, including ACE inhibitors, for each patient. By customizing therapy based on patient-specific factors, healthcare providers can enhance treatment effectiveness while minimizing the risk of adverse effects. This personalized medicine approach not only improves patient outcomes but also promotes medication adherence. In response to this trend, pharmaceutical companies are increasingly focusing on developing more targeted ACE inhibitors that align with personalized treatment strategies. This evolution towards personalized medicine is expected to revolutionize the management of cardiovascular diseases, ensuring that patients receive the most suitable treatment tailored to their individual needs.

Segmental Insights

Type Insights

Based on type, Sulfhydryl-containing agents segment dominated the North America ACE Inhibitors Market. This is ascribed due to their distinctive mechanism of action and clinical efficacy. Captopril, as a pioneer in this class, was the first ACE inhibitor developed, setting a standard in cardiovascular therapy that persists to this day. Its rapid onset of action and effectiveness in managing conditions like hypertension and heart failure make it a preferred choice among healthcare professionals. By interacting with the ACE enzyme through its sulfhydryl group, Captopril and similar agents offer an alternative approach to traditional ACE inhibitors, providing diversity in treatment options and catering to specific patient needs. This diversity contributes significantly to the dominance of sulfhydryl-containing agents in the ACE Inhibitors Market, reinforcing their pivotal role in cardiovascular care.

Dosage Form Insights

Based on dosage form, oral tablets have established dominance in the ACE Inhibitors Market as the primary dosage form for these medications. This is due to their convenient administration, patient-friendly nature, and the pharmaceutical sector's capability to develop efficient and user-friendly formulations. Oral tablets provide accurate dosing, streamlining the treatment of hypertension and cardiovascular conditions. They are readily accessible, cost-effective, and offer convenience to patients, thereby promoting adherence to treatment plans. This dominance is bolstered by ongoing research and development initiatives aimed at enhancing the formulation, effectiveness, and tolerability of ACE inhibitor tablets. Given their established efficacy, oral tablets maintain their status as the preferred option in the ACE Inhibitors Market.

Country Insights

The United States dominated the ACE Inhibitors Market. This due to the high prevalence of cardiovascular diseases and hypertension in the country drives the demand for ACE inhibitors. The well-established healthcare infrastructure, advanced medical research, and a large patient population contribute to the market's growth. The presence of key pharmaceutical companies focusing on cardiovascular medications and a proactive regulatory environment further solidify the market's dominance in the United States. The emphasis on personalized medicine and innovative treatment approaches also positions the U.S. as a leader in advancing ACE inhibitor therapies, fostering continuous market expansion.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Key Market Players

- Pfizer Inc
- Novartis AG
- Johnson & Johnson
- Merck KGaA
- Sanofi S.A
- Bayer AG
- United Therapeutics Corporation
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
- Takeda Pharmaceuticals Company Ltd.

Report Scope:

In this report, the North America ACE Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

□□North America ACE Inhibitors Market, By Type:

- o Sulfhydryl-containing Agents
- o Dicarboxylate-containing Agents.
- o Phosphonate-containing Agents

□□North America ACE Inhibitors Market, By Drug:

- o Ramipril
- o Enalapril
- o Benazepril
- o Fosinopril
- o Captopril
- o Moexipril
- o Others

□□North America ACE Inhibitors Market, By Dosage Form:

- o Oral Tablets
- o Oral Solutions

□□North America ACE Inhibitors Market, By Application:

- o Heart Failure
- o Chronic Kidney Disease
- o Hypertension
- o Diabetes
- o Heart Attack
- o Others

□□North America ACE Inhibitors Market, By End user:

- o Hospitals
- o Online Drug Stores
- o Others

□□North America ACE Inhibitors Market, By Country:

- o United States
- o Canada
- o Mexico

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the ACE Inhibitors Market.

Available Customizations:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America ACE Inhibitors market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

☐ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations
2. Research Methodology
 - 2.1. Objective of the Study
 - 2.2. Baseline Methodology
 - 2.3. Key Industry Partners
 - 2.4. Major Association and Secondary Sources
 - 2.5. Forecasting Methodology
 - 2.6. Data Triangulation & Validation
 - 2.7. Assumptions and Limitations
3. Executive Summary
 - 3.1. Overview of the Market
 - 3.2. Overview of Key Market Segmentations
 - 3.3. Overview of Key Market Players
 - 3.4. Overview of Key Regions/Countries
 - 3.5. Overview of Market Drivers, Challenges, Trends
4. North America ACE Inhibitors Market Outlook
 - 4.1. Market Size & Forecast
 - 4.1.1. By Value
 - 4.2. Market Share & Forecast
 - 4.2.1. By Type (Sulphydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents)
 - 4.2.2. By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others)
 - 4.2.3. By Dosage Form (Oral Tablets, Oral Solutions)
 - 4.2.4. By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others)
 - 4.2.5. By End user (Hospitals, Online Drug Stores, Others)
 - 4.2.6. By Country
 - 4.2.7. By Company (2023)
 - 4.3. Market Map
 - 4.3.1. By Type
 - 4.3.2. By Drug
 - 4.3.3. By Dosage Form
 - 4.3.4. By Application
 - 4.3.5. By End user
 - 4.3.6. By Country
5. United States ACE Inhibitors Market Outlook
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2. Market Share & Forecast
 - 5.2.1. By Type
 - 5.2.2. By Drug
 - 5.2.3. By Dosage Form
 - 5.2.4. By Application
 - 5.2.5. By End User
- 6. Mexico ACE Inhibitors Market Outlook
 - 6.1. Market Size & Forecast
 - 6.1.1. By Value
 - 6.2. Market Share & Forecast
 - 6.2.1. By Type
 - 6.2.2. By Drug
 - 6.2.3. By Dosage Form
 - 6.2.4. By Application
 - 6.2.5. By End User
- 7. Canada ACE Inhibitors Market Outlook
 - 7.1. Market Size & Forecast
 - 7.1.1. By Value
 - 7.2. Market Share & Forecast
 - 7.2.1. By Type
 - 7.2.2. By Drug
 - 7.2.3. By Dosage Form
 - 7.2.4. By Application
 - 7.2.5. By End User
- 8. Market Dynamics
 - 8.1. Drivers
 - 8.2. Challenges
- 9. Market Trends & Developments
 - 9.1. Recent Developments
 - 9.2. Product Launches
 - 9.3. Mergers & Acquisitions
- 10. North America ACE Inhibitors Market: SWOT Analysis
- 11. Porter's Five Forces Analysis
 - 11.1. Competition in the Industry
 - 11.2. Potential of New Entrants
 - 11.3. Power of Suppliers
 - 11.4. Power of Customers
 - 11.5. Threat of Substitute Product
- 12. Competitive Landscape
 - 12.1. Pfizer Inc
 - 12.1.1. Business Overview
 - 12.1.2. Company Snapshot
 - 12.1.3. Product & Services
 - 12.1.4. Financials (In case of listed)
 - 12.1.5. Recent Developments
 - 12.1.6. SWOT Analysis
 - 12.2. Novartis AG

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3. Johnson & Johnson
- 12.4. Merck KGaA
- 12.5. Sanofi S.A
- 12.6. Bayer AG
- 12.7. United Therapeutics Corporation
- 12.8. Teva Pharmaceutical Industries Ltd.
- 12.9. Bristol-Myers Squibb Company
- 12.10. Takeda Pharmaceuticals Company Ltd.
- 13. Strategic Recommendations
- 14. About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America ACE Inhibitors Market By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drugs (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others), By End user (Hospitals, Online Drug Stores, Others), By Country, Competition, Forecast and Opportunities, 2019-2029F

Market Report | 2024-10-04 | 136 pages | TechSci Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4400.00
	Multi-User License	\$5400.00
	Custom Research License	\$8400.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com